Abstract

Purpose: To investigate whether the use of levothyroxine was associated with breast cancer risk. Methods: We conducted a population-based case–control study in Taiwan. Cases consisted of all patients who were aged 20 years and older, and had a first-time diagnosis of breast cancer for the period between 2001 and 2011. The controls were matched to the cases by age, sex, year, and month of diagnosis. Adjusted odd ratios (ORs) and 95% confidence intervals (CIs) were estimated by a conditional logistic regression. Results: We examined 65,491 breast cancer cases and 261,964 controls. We found that use of levothyroxine was associated with a significant increase in breast cancer risk (OR 1.24, 95% CI 1.15–1.33; P < 0.001). Compared with no use levothyroxine, the adjusted odd ratio was 1.22 (95% CI 1.11–1.35; P = 0.01) for the group having been prescribed levothyroxine 2 months to 1 year, and 1.26 (95% CI 1.12–1.41; P < 0.01) for the group with more than 1 year. When stratified by age, the adjusted odd ratio was 1.45 (95% CI 1.23–1.71; P < 0.01) for the patients aged 65 years or more and 1.19 (95% CI 1.09–1.29, P < 0.01) for the patients aged less than 65 years. Conclusion: The results of the present study are the first to suggest that levothyroxine use increased the risk of breast cancer. However, a larger long-term prospective randomized-controlled trial specifically designed to assess the effect of levothyroxine use on the risk of developing breast cancer is needed.

Original languageEnglish
Pages (from-to)389-396
Number of pages8
JournalArchives of Gynecology and Obstetrics
Volume298
Issue number2
DOIs
Publication statusPublished - Aug 1 2018

Fingerprint

Thyroxine
Confidence Intervals
Breast Neoplasms
Odds Ratio
Population
Taiwan
Randomized Controlled Trials
Logistic Models

Keywords

  • Breast cancer
  • Case–control study
  • Levothyroxine
  • Odd ratio
  • Thyroid disease

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

Levothyroxine use and the risk of breast cancer : a nation-wide population-based case–control study. / Wu, Chieh Chen; Yu, Ya Yu; Yang, Hsuan Chia; Nguyen, Phung Anh; Poly, Tahmina Nasrin; Islam, Md Mohaimenul; Iqbal, Usman; Khan, Hafash Arshed Ali; Wang, Yao Chin; Cheng, Yung Tzu; Li, Yu Chuan; Jian, Wen Shan.

In: Archives of Gynecology and Obstetrics, Vol. 298, No. 2, 01.08.2018, p. 389-396.

Research output: Contribution to journalArticle

Wu, Chieh Chen ; Yu, Ya Yu ; Yang, Hsuan Chia ; Nguyen, Phung Anh ; Poly, Tahmina Nasrin ; Islam, Md Mohaimenul ; Iqbal, Usman ; Khan, Hafash Arshed Ali ; Wang, Yao Chin ; Cheng, Yung Tzu ; Li, Yu Chuan ; Jian, Wen Shan. / Levothyroxine use and the risk of breast cancer : a nation-wide population-based case–control study. In: Archives of Gynecology and Obstetrics. 2018 ; Vol. 298, No. 2. pp. 389-396.
@article{68c1f70768ff429bbf2511263e6718bf,
title = "Levothyroxine use and the risk of breast cancer: a nation-wide population-based case–control study",
abstract = "Purpose: To investigate whether the use of levothyroxine was associated with breast cancer risk. Methods: We conducted a population-based case–control study in Taiwan. Cases consisted of all patients who were aged 20 years and older, and had a first-time diagnosis of breast cancer for the period between 2001 and 2011. The controls were matched to the cases by age, sex, year, and month of diagnosis. Adjusted odd ratios (ORs) and 95{\%} confidence intervals (CIs) were estimated by a conditional logistic regression. Results: We examined 65,491 breast cancer cases and 261,964 controls. We found that use of levothyroxine was associated with a significant increase in breast cancer risk (OR 1.24, 95{\%} CI 1.15–1.33; P < 0.001). Compared with no use levothyroxine, the adjusted odd ratio was 1.22 (95{\%} CI 1.11–1.35; P = 0.01) for the group having been prescribed levothyroxine 2 months to 1 year, and 1.26 (95{\%} CI 1.12–1.41; P < 0.01) for the group with more than 1 year. When stratified by age, the adjusted odd ratio was 1.45 (95{\%} CI 1.23–1.71; P < 0.01) for the patients aged 65 years or more and 1.19 (95{\%} CI 1.09–1.29, P < 0.01) for the patients aged less than 65 years. Conclusion: The results of the present study are the first to suggest that levothyroxine use increased the risk of breast cancer. However, a larger long-term prospective randomized-controlled trial specifically designed to assess the effect of levothyroxine use on the risk of developing breast cancer is needed.",
keywords = "Breast cancer, Case–control study, Levothyroxine, Odd ratio, Thyroid disease",
author = "Wu, {Chieh Chen} and Yu, {Ya Yu} and Yang, {Hsuan Chia} and Nguyen, {Phung Anh} and Poly, {Tahmina Nasrin} and Islam, {Md Mohaimenul} and Usman Iqbal and Khan, {Hafash Arshed Ali} and Wang, {Yao Chin} and Cheng, {Yung Tzu} and Li, {Yu Chuan} and Jian, {Wen Shan}",
year = "2018",
month = "8",
day = "1",
doi = "10.1007/s00404-018-4837-y",
language = "English",
volume = "298",
pages = "389--396",
journal = "Archives of Gynecology and Obstetrics",
issn = "0932-0067",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Levothyroxine use and the risk of breast cancer

T2 - a nation-wide population-based case–control study

AU - Wu, Chieh Chen

AU - Yu, Ya Yu

AU - Yang, Hsuan Chia

AU - Nguyen, Phung Anh

AU - Poly, Tahmina Nasrin

AU - Islam, Md Mohaimenul

AU - Iqbal, Usman

AU - Khan, Hafash Arshed Ali

AU - Wang, Yao Chin

AU - Cheng, Yung Tzu

AU - Li, Yu Chuan

AU - Jian, Wen Shan

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Purpose: To investigate whether the use of levothyroxine was associated with breast cancer risk. Methods: We conducted a population-based case–control study in Taiwan. Cases consisted of all patients who were aged 20 years and older, and had a first-time diagnosis of breast cancer for the period between 2001 and 2011. The controls were matched to the cases by age, sex, year, and month of diagnosis. Adjusted odd ratios (ORs) and 95% confidence intervals (CIs) were estimated by a conditional logistic regression. Results: We examined 65,491 breast cancer cases and 261,964 controls. We found that use of levothyroxine was associated with a significant increase in breast cancer risk (OR 1.24, 95% CI 1.15–1.33; P < 0.001). Compared with no use levothyroxine, the adjusted odd ratio was 1.22 (95% CI 1.11–1.35; P = 0.01) for the group having been prescribed levothyroxine 2 months to 1 year, and 1.26 (95% CI 1.12–1.41; P < 0.01) for the group with more than 1 year. When stratified by age, the adjusted odd ratio was 1.45 (95% CI 1.23–1.71; P < 0.01) for the patients aged 65 years or more and 1.19 (95% CI 1.09–1.29, P < 0.01) for the patients aged less than 65 years. Conclusion: The results of the present study are the first to suggest that levothyroxine use increased the risk of breast cancer. However, a larger long-term prospective randomized-controlled trial specifically designed to assess the effect of levothyroxine use on the risk of developing breast cancer is needed.

AB - Purpose: To investigate whether the use of levothyroxine was associated with breast cancer risk. Methods: We conducted a population-based case–control study in Taiwan. Cases consisted of all patients who were aged 20 years and older, and had a first-time diagnosis of breast cancer for the period between 2001 and 2011. The controls were matched to the cases by age, sex, year, and month of diagnosis. Adjusted odd ratios (ORs) and 95% confidence intervals (CIs) were estimated by a conditional logistic regression. Results: We examined 65,491 breast cancer cases and 261,964 controls. We found that use of levothyroxine was associated with a significant increase in breast cancer risk (OR 1.24, 95% CI 1.15–1.33; P < 0.001). Compared with no use levothyroxine, the adjusted odd ratio was 1.22 (95% CI 1.11–1.35; P = 0.01) for the group having been prescribed levothyroxine 2 months to 1 year, and 1.26 (95% CI 1.12–1.41; P < 0.01) for the group with more than 1 year. When stratified by age, the adjusted odd ratio was 1.45 (95% CI 1.23–1.71; P < 0.01) for the patients aged 65 years or more and 1.19 (95% CI 1.09–1.29, P < 0.01) for the patients aged less than 65 years. Conclusion: The results of the present study are the first to suggest that levothyroxine use increased the risk of breast cancer. However, a larger long-term prospective randomized-controlled trial specifically designed to assess the effect of levothyroxine use on the risk of developing breast cancer is needed.

KW - Breast cancer

KW - Case–control study

KW - Levothyroxine

KW - Odd ratio

KW - Thyroid disease

UR - http://www.scopus.com/inward/record.url?scp=85049167615&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049167615&partnerID=8YFLogxK

U2 - 10.1007/s00404-018-4837-y

DO - 10.1007/s00404-018-4837-y

M3 - Article

AN - SCOPUS:85049167615

VL - 298

SP - 389

EP - 396

JO - Archives of Gynecology and Obstetrics

JF - Archives of Gynecology and Obstetrics

SN - 0932-0067

IS - 2

ER -